Latest News
-
13th August 2026
Peer-Reviewed Publication of AT278 Study in Diabetes, Obesity and Metabolism journal
-
3rd August 2026
Clarivate report – Companies to Watch 2026: Seven innovators shaping next-generation obesity therapies
-
30th July 2026
Diabetes, Obesity and Metabolism article – A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra-Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI
News
For regulatory news click here
-
13/08/2026
Peer-Reviewed Publication of AT278 Study in Diabetes, Obesity and Metabolism journal
-
30/07/2026
Diabetes, Obesity and Metabolism article – A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra-Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI
-
03/08/2026
Clarivate report – Companies to Watch 2026: Seven innovators shaping next-generation obesity therapies
-
18/05/2026
Upcoming conference attendance
-
28/04/2026
BioSpace podcast – The next era of diabetes management
-
09/03/2026
Arecor to present at Oppenheimer Annual Healthcare MedTech & Services Conference (16 March 2026)
-
23/02/2026
Arecor talks to Biotech TV
-
07/01/2026
Arecor and Sequel Med Tech Fireside Panel Discussion